<DOC>
	<DOCNO>NCT02839889</DOCNO>
	<brief_summary>The purpose study determine naloxegol use treatment opioid-induced constipation patient cancer pain . This phase 4 study consist two week randomize double blind period follow two week open-label period .</brief_summary>
	<brief_title>Tolerability , Safety , Feasibility Naloxegol Patients With Cancer OIC ( Opioid Induced Constipation )</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Men woman age 18 older : Women child bear potential must negative urine pregnancy test Screening/Opioid Induced Constipation ( OIC ) Confirmation/Baseline period , history sexual activity consistent use effective birth control method least 12 week prior study , agreement sexual activity method birth control continue study period 8 week end ; male patient sexually active must agree use barrier method contraception ( condom spermicide ) first dose Investigational Product 12 week last dose Able follow instruction English , give informed consent answer patient report outcome ( PRO ) question himself/herself ; patient provide write informed consent initiation studyrelated procedure Active cancer type investigatorestimated life expectancy ≥ 8 week Palliative Performance Status scale score ≥ 30 % Patients receive concurrent chemotherapy must receive recovered minimum 1 cycle current chemotherapy regimen upon consent study consider stable opinion investigator Chronic cancerrelated pain , define pain minimum ≥2 week review investigator , attribute neoplasm treatment Daily treatment opioid drug take dose equal great 20 milligram ( mg ) morphine equivalent least one week , daytoday daily fluctuation great 25 % expectation decrease great 25 % increase great 50 % study period . Patients may may stable laxative regimen , define daily use stable dose &gt; 7 day ; patient take stable dose , must willing remain regimen 7 day confirmation period without titration adjustment . History constipation , define history participation OIC Screening/OIC Confirmation/Baseline period Patient history must include few 3 rescuefree bowel movement ( RFBM ) per week two week prior screen experience least one follow symptom least onequarter Bowel Movements ( BM ) experience prior two week : hard/lumpy stool , strain , sensation incomplete evacuation/anorectal obstruction ( rescuefree BMs define use laxative already take daily laxative , take daily laxative , use additional laxative ) . Confirmation 7day OIC confirmation period must include experience &lt; 3 rescuefree BMs plus report ≥ 1 follow symptom least 1 BM record diary OIC confirmation period : Bristol Stool Scale ( BSS ) stool type 1 2 ; moderate , severe , severe straining ; incomplete BM . Cancerrelated/medical comorbidityrelated Patients past current history intraabdominal neoplasm AND clinical finding , review investigator , may increase risk bowel perforation An active condition associate clinically significant brain pathology , include know brain metastasis , meningeal metastasis , past traumatic brain injury , multiple sclerosis , uncontrolled epilepsy sign symptom compromise blood brain barrier Patients expect undergo first course chemotherapy regimen study period , patient receive vinca alkaloid within 2 month , patient history vincaassociated GI autonomic neuropathy and/or constipation , patient receive chemotherapy regimen include VEGFinhibitor ( e.g. , bevacizumab , sorafenib ) . Requiring radiation therapy diaphragm pelvis 2 week prior Visit 1 ( screen ) and/or study Any significant and/or progressive condition ( medical , neurological , psychiatric metabolic ) symptom could increase risk participation study affect interpretation study data determine investigator ( e.g. , uncontrolled hypothyroidism , inadequately control clinical depression , poorly control seizure disorder ) Hemorrhagic diathesis Expected surgical procedure require general anesthesia study period Other gastrointestinal disorder Medical condition treatment , judgment investigator , may associate diarrhea , intermittent loose stool , constipation , ( e.g. , active diverticular disease , peritonitis cause , inflammatory bowel disease , active irritable bowel syndrome , chronic idiopathic constipation ) . Any condition could affect absorption metabolism study drug ( e.g. , malabsorption syndrome , severe liver disease ) judge investigator Evidence fecal impaction either physical xray exam Known suspect mechanical GI obstruction Current peritoneal catheter intraperitoneal chemotherapy dialysis Fecal ostomy History fecal incontinence History bowel surgery within 60 day screen period Any potential nonopioid cause bowel dysfunction opinion investigator might contributor constipation Painrelated Receiving opioid medication less daily dose schedule Severe background pain ( eg , typical average daily pain intensity rating 8 10 11point NRS ) refractory opioid therapy Any following finding condition enrollment randomization visit : Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal ( ULN ) and/or serum bilirubin &gt; 2 x ULN ( unless elevation due Gilbert 's syndrome ) Calculated Creatinine clearance &lt; 30 ml/min A Fridericia correct QT interval ( QTcF ) &gt; 500 msec screening , history myocardial infarction within 6 month randomization , symptomatic congestive heart failure despite treatment , unstable angina , symptomatic peripheral vascular disease Active substance alcohol use , opinion investigator , may compromise patient 's ability comply study instruction Use prohibit medication list Section 5.5 Pregnancy lactation Known history intolerance hypersensitivity alvimopan , methylnaltrexone , peripherally act opioid antagonist component tablet Involvement plan and/or conduct study ( applies AstraZeneca staff , staff study site , thirdparty vendor ) Any receipt investigational medication within 30 day screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>